Firms To Be Held More Accountable For Completing Postmarket Studies – FDA
This article was originally published in The Gray Sheet
Executive Summary
FDA plans to shift the tracking of postmarket studies from the Office of Device Evaluation to the Office of Surveillance & Biometrics by year-end to enable ODE to better meet MDUFMA goals